Therapeutic Benefits of Selenium in Hematological Malignancies

Ehudin, Melanie; Golla, Upendarrao; Trivedi, Devnah; Potlakayala, Shobha; Rudrabhatla, Sairam; Desai, Dhimant; Dovat, Sinisa; Claxton, David F.; Sharma, Aruna

doi:10.3390/ijms23147972

Cited by 10 publications

(7 citation statements)

References 216 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, it was shown that Se-induced P53 activation may downregulate Bcl-2 and upregulate Bax, which would induce Ehrlich cancer cells to undergo apoptosis (Ramakrishnan et al, 2009). These data agree with earlier research that Se promotes apoptosis in hematological malignancies, (Ehudin et al, 2022) leukemia and lymphoma cells (Wu et al, 2014) and esophageal cancer (Ahsan et al, 2022). It has been reported that, glutathione and Se interacted to form hydrogen selenide, or selenodiglutathione, which causes cytotoxicity in the form of DNA damage, ROS generation and cell death (Kim et al, 2021;Lipinski, 2017).…”

Section: Discussionsupporting

confidence: 90%

Selenium suppressed growth of Ehrlich solid tumor and improved health of tumor‐bearing mice

Hekal,

Amer,

Amer

et al. 2024

J Exp Zool Pt A

View full text Add to dashboard Cite

Selenium (Se) is an important micronutritional biomolecule in cancer therapy. The current work evaluated the anticancer effect of Se and its ability to improve health of mice with solid Ehrlich carcinoma implanted subcutaneously. Four groups of five female BALB/c mice each were assembled. Ehrlich tumor cells were engrafted into two of them, either with or without Se therapy. The other groups served as control groups, either with or without Se treatment. Se treatment resulted in a notable decrease in both tumor volume and animal body mass in tumor‐bearing mice. Treatment with Se markedly increased oxidative stress in tumor while ameliorating oxidative stress in sera of tumors‐bearing mice. Similarly, treatment with Se resulted in downregulation of inflammatory cytokines (TNF‐α and IL‐6) while increasing IL‐10 in serum of tumor‐bearing mice. Conversely, selenium increased TNF‐ α and IL‐6 and decreased IL‐10 in tumor suggesting disruption of tumor immunity. The increased oxidative stress and inflammation in tumor tissue dysregulated cell cycle phases with increase apoptotic tumor cells population in G0/G1 phase. This is supported by the increased levels apoptotic regulating proteins (Bax and caspase‐3 and P‐53) while decreasing Bcl‐2 in the tumor tissue. Treatment with Se also resulted in increased comet parameters indicating DNA damage of tumor cells. Histopathological examination revealed a significant decrease in a number of neoplastic cells within tumor of mice that treated with Se. In conclusion, these findings suggest that Se therapy significantly suppressed solid tumor proliferation and growth while mitigating the health status of tumor‐bearing mice.

show abstract

Section: Discussionsupporting

confidence: 90%

Selenium suppressed growth of Ehrlich solid tumor and improved health of tumor‐bearing mice

Hekal,

Amer,

Amer

et al. 2024

J Exp Zool Pt A

View full text Add to dashboard Cite

show abstract

“…Historically, Se was considered both a potential toxin and a protective element. Contemporary research has revealed that Se can have both beneficial and harmful effects on organisms, including the nervous system and the heart [ 311 ]. Several human studies have demonstrated that supplementing standard-of-care chemotherapies (such as cisplatin, doxorubicin, cyclophosphamide, and busulfan) with Se (in the form of sodium selenite or organic selenium) reduces toxicity without compromising therapeutic efficacy [ 310 ].…”

Section: Can Antioxidants Act As Pro-oxidants?mentioning

confidence: 99%

Antioxidant Metabolism Pathways in Vitamins, Polyphenols, and Selenium: Parallels and Divergences

Andrés,

Pérez de la Lastra,

Juan

et al. 2024

IJMS

View full text Add to dashboard Cite

Free radicals (FRs) are unstable molecules that cause reactive stress (RS), an imbalance between reactive oxygen and nitrogen species in the body and its ability to neutralize them. These species are generated by both internal and external factors and can damage cellular lipids, proteins, and DNA. Antioxidants prevent or slow down the oxidation process by interrupting the transfer of electrons between substances and reactive agents. This is particularly important at the cellular level because oxidation reactions lead to the formation of FR and contribute to various diseases. As we age, RS accumulates and leads to organ dysfunction and age-related disorders. Polyphenols; vitamins A, C, and E; and selenoproteins possess antioxidant properties and may have a role in preventing and treating certain human diseases associated with RS. In this review, we explore the current evidence on the potential benefits of dietary supplementation and investigate the intricate connection between SIRT1, a crucial regulator of aging and longevity; the transcription factor NRF2; and polyphenols, vitamins, and selenium. Finally, we discuss the positive effects of antioxidant molecules, such as reducing RS, and their potential in slowing down several diseases.

show abstract

“…Accordingly, the deficiency of Se in serum is linked with aberrant immune functions, cancer, cardiac, and inflammatory diseases [42]. Recently, we reviewed the anticancer effects of Se and SeCs alone or in combination with standard therapy (chemo-or radiation) for different hematological malignancies including Leukemias [43]. The supplementation of Se and/or Se-containing food was shown to have chemopreventive effects in animals and humans with some contradictory reports [44].…”

Section: Role Of Se and Seps In Lymphomamentioning

confidence: 99%

Chemopreventive Effects of Selenium and Selenocompounds in the Treatment of Lymphoma

Golla

Dallavalasa

2022

BioMed

Self Cite

View full text Add to dashboard Cite

Lymphomas have been increasing at an alarming rate globally and causing deaths worldwide due to the lack of effective therapies. Among different pharmacological agents, selenium (Se) and selenium-related compounds are widely tested and have gained interest as anticancer agents due to their selectivity to cancer and high efficacy for lymphoma treatment over recent decades. Se is a trace non-metallic element identified as an essential micronutrient that mediates a range of biological functions after incorporation into selenoproteins (SePs), and thus affects the overall quality of human health. Specifically, low levels of Se in serum have been linked with aberrant immune functions, cancer, inflammatory diseases, and predictive of worse outcomes in patients with hematological malignancies including lymphoma. Over the past few years, a number of promising selenium compounds (SeCs) have been developed to mimic and alter the functions of SePs to achieve pharmacological interventions such as anticancer, antioxidant, and anti-inflammatory activities with minimal adverse effects by suitable chemical substitution. Here, we have reviewed various lymphoma types and their molecular characterization, along with emphasis on the potential role of Se and SeCs as anti-cancer agents for lymphoma treatment. In addition, we have discussed various pros and cons associated with the usage of Se/SeCs for selectively targeting cancers including lymphomas.

show abstract

Therapeutic Benefits of Selenium in Hematological Malignancies

Cited by 10 publications

References 216 publications

Selenium suppressed growth of Ehrlich solid tumor and improved health of tumor‐bearing mice

Selenium suppressed growth of Ehrlich solid tumor and improved health of tumor‐bearing mice

Antioxidant Metabolism Pathways in Vitamins, Polyphenols, and Selenium: Parallels and Divergences

Chemopreventive Effects of Selenium and Selenocompounds in the Treatment of Lymphoma

Contact Info

Product

Resources

About